Cargando…

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma

Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin melanoma but around half of all patients develop resistance early or late during treatment. The situation is even worse for patients with metastatic uveal melanoma (UM). Here we hypothesized that the immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sah, Vasu R., Karlsson, Joakim, Jespersen, Henrik, Lindberg, Mattias F., Nilsson, Lisa M., Ny, Lars, Nilsson, Jonas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles: Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245557/ https://www.ncbi.nlm.nih.gov/pubmed/34753889 http://dx.doi.org/10.1097/CMR.0000000000000791

Ejemplares similares

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
por: Sah, Vasu R., et al.
Publicado: (2023)

Molecular profiling of driver events in metastatic uveal melanoma
por: Karlsson, Joakim, et al.
Publicado: (2020)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2018)

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020)

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
por: Jespersen, Henrik, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
por: Einarsdottir, Berglind O., et al.
Publicado: (2014)

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
por: Jespersen, Henrik, et al.
Publicado: (2019)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
por: Gérard, Alexandre, et al.
Publicado: (2021)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour
por: Kölby, L, et al.
Publicado: (2005)

Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
por: Saltari, Annalisa, et al.
Publicado: (2021)

Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary
por: Bagge, Roger Olofsson, et al.
Publicado: (2018)

Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs
por: Forsberg, Elin M. V., et al.
Publicado: (2023)

Epigenetics in the Diagnosis and Therapy of Malignant Melanoma
por: Santourlidis, Simeon, et al.
Publicado: (2022)

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
por: Eroglu, Zeynep, et al.
Publicado: (2022)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells
por: Muralidharan, Somsundar V, et al.
Publicado: (2020)

Application of Liquid Biopsies in Cancer Targeted Therapy
por: Sumanasuriya, S, et al.
Publicado: (2017)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
por: Schetters, Sjoerd T T, et al.
Publicado: (2020)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma—A Nation-Wide Swedish Population-Based Retrospective Register Study
por: Katsarelias, Dimitrios, et al.
Publicado: (2020)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion
por: Hofving, Tobias, et al.
Publicado: (2021)

History of Ozone in Therapeutics
por: Debierre,, et al.
Publicado: (1887)

The Therapeutical Properties of Koumys
Publicado: (1874)

The Therapeutic Employment of the Fumes of Opium
Publicado: (1869)

Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy
por: Tamborino, Giulia, et al.
Publicado: (2022)

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs
por: Inci, Kamuran, et al.
Publicado: (2023)

Epigenetics, microRNA, and addiction
por: Kenny, Paul J.
Publicado: (2014)

The Physiological and Therapeutic Action of Acetanilide or Antifebrin
por: Weill,, et al.
Publicado: (1887)

Cannot write session to /tmp/vufind_sessions/sess_u4mr64h6gm1dikpnav1b8kpo9k